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Stem cell therapy offers a promising new option for the treatment of complex diseases. While there are ethical and tumourigenic concerns with embryonic stem cells, adult stem cells are already used successfully and safely to treat patients. Multipotent marrow stromal cells (MSCs) are bone marrow derived adherent fibroblastlike cells that differentiate into a large number of cell types, have immunomodulatory properties and secrete cytokines and growth factors [1], together making them potential ideal candidates for therapies of various disorders [2]. MSCs have been used successfully to treat a number of diseases in animal models and are currently used in clinical trials to treat different diseases including myocardial infarction, graft versus host disease, Crohn's disease and others
.
The specific mechanism of action of MSCs in organoprotection and repair does not involve, as initially thought, differentiation into resident parenchymal cells but rather paracrine actions, including growth factor secretion, as well as immunomodulatory functions [4, 5] . [6] . Growth factors including IGF-1 [7] , EGF and vasculotropic factors [8] have been shown to be mediators of renal repair and this effect can be reproduced using MSC conditioned medium [9] . Paracrine factors secreted by MSCs also have been shown to be important in the process of wound healing by recruiting macrophages and thereby enhancing repair [10] . VEGF is the major factor that regulates vessel growth in normal as well as injured tissues and is highly secreted by MSCs [11] [12] [13] (Fig. 1, right [15, 16] [17] . Vascular damage is an early and important mediator of AKI [15] , and also leads to long-term damage and progressive loss of renal function [18] . VEGF is the major angiogenic factor that is important for vascular maintenance after AKI. Renal ischemia inhibits VEGF expression by multiple mechanisms, shifting the balance from a pro-angiogenic to an anti-angiogenic milieu, thereby inhibiting renal repair and paving the way to long-term progressive loss of renal function [19] . MSCs express VEGF [8] amongst other growth factors and have been shown to exert paracrine actions that are renoprotective and enhance recovery from AKI [14] . Recently, IGF-1 has been implicated as a paracrine mediator of renoprotection in a cisplatinum model of AKI [7] . Basile has demonstrated that VEGF is down regulated after AKI and a long-term consequence of AKI is decreased microvessel density and impaired renal concentrating ability [18, 19] . MSC treatment early in the course of AKI might appear thus beneficial for the long-term outcome after AKI.
MSCs are effective in reducing renal injury and enhancing recovery of renal function in animal models of acute kidney injury (AKI), including an ischemia/reperfusion as well as a cisplatinum toxicity model, but do not or only rarely contribute to differentiated renal cell types, e.g. tubular cells or endothelial cells
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panel). Conditioned medium from VEGF knockdown MSC exerted less proliferative activity on proximal tubular cells compared to regular conditioned medium from MSCs treated with irrelevant siRNAs (P ϭ 0.029) or control medium (S.F. [serumfree medium], P ϭ 0.038) (Fig. 2), thereby demonstrating the mitogenic activity of VEGF in tubular cells. Addition of 10 ng/ml VEGF restored proliferative activity of the conditioned medium.
VEGF knockdown reduces renoprotection of MSCs
In order to investigate the applicability of our in vitro results to the in vivo situation, we studied the comparative renoprotective effects of wild type MSCs and to VEGF knockdown MSCs in the standard model of ischemia/reperfusion AKI. Female SD rats were subjected to 48 min. of bilateral renal pedicle clamping to induce severe AKI. Regular MSCs were renoprotective as shown by lower serum creatinine values on days 1 and 7 compared to vehicle injection (Fig. 3A). VEGF knockdown rendered MSCs less effective in exerting renoprotection and recovery, which was highly significant at day 7 (P ϭ 0.0004). Survival of animals treated with VEGF knockdown MSCs during the first three days after clamping was lower compared to MSC treated animals (Fig. 2B).
Decreased microvessel density after treatment with VEGF knockdown MSCs
VEGF is the major mediator of vascular growth and repair and microvascular injury is an important pathophysiological component of AKI
In conclusion, we have identified VEGF as an important mediator of the paracrine actions of MSCs in the treatment of AKI in vitro and in vivo. 
